TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01099345

Intervention type: PROCEDURE
Intervention: cystometry (CMG)
Description: recording device measuring pressures though catheters placed in bladder and rectum

Intervention type: PROCEDURE
Intervention: cystometry (CMG)
Description: recording device measuring pressures though catheters placed in bladder and rectum

Intervention type: PROCEDURE
Intervention: polysomnography (PSG)
Description: Recording device measuring sleep activity through electrodes attached to the subject

Intervention type: PROCEDURE
Intervention: polysomnography (PSG)
Description: Recording device measuring sleep activity through electrodes attached to the subject
Study: NCT01001585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane
Description: During induction, concentration of inspired sevoflurane will begin at .5%, and slowly increased by 0.5% every two minutes, until a Bispectral Index (BIS) of 60 or less is reached, which will take approximately 10 minutes.
Study: NCT03855072

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: customized fixation plate
Description: * All cases will undergo one surgery under general anesthesia.~* Incision was made medial to external oblique ridge from the asendindg ramus to second molar region~* Amucoperiosteal flap was reflected to expose the lateral mandibular ramus to the posterior border and the sigmoid notch~* The intraoral vertical osteotomy is accomplished by using an oscillating saw to make the cut from the sigmoid notch through the inferior border of the mandible.~* 3D virtual planning and 3D mandible model represented fom CBCT in MIMICS~* The customized fixation plate is positioned to fix the proximal and distal segment together after setback

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: maxillomandibular fixation
Description: * All cases will undergo one surgery under general anesthesia.~* incision was made medial to external oblique ridge from the asendindg ramus to second molar region .~* The intraoral vertical osteotomy is accomplished by using an oscillating saw to make the cut from the sigmoid notch through the inferior border of the mandible.~* Patient is placed in maxillomandibular fixation (MMF) using a prefabricated occlusal splint to assure accuracy of the mandibular position.
Study: NCT04642144

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yerba mate infusion
Description: Yerba mate infusion intervention is characterized by the consumption of the infusion of yerba mate for 7 days preceding the test, with consumption of the infusion right before the exercise protocol test, without consumption of a carbohydrate-based meal, keeping the individual fasted.~Yerba mate and carbohydrate intervention is characterized by the consumption of the infusion of yerba mate for 7 days preceding the test, with consumption of a meal based on carbohydrate right before the exercise protocol test with another infusion of yerba mate.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yerba mate infusion
Description: Yerba mate infusion intervention is characterized by the consumption of the infusion of yerba mate for 7 days preceding the test, with consumption of the infusion right before the exercise protocol test, without consumption of a carbohydrate-based meal, keeping the individual fasted.~Yerba mate and carbohydrate intervention is characterized by the consumption of the infusion of yerba mate for 7 days preceding the test, with consumption of a meal based on carbohydrate right before the exercise protocol test with another infusion of yerba mate.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate meal
Description: Carbohydrate meal intervention is characterized by the consumption of a carbohydrate-based meal right before the exercise protocol test, without consumption yerba mate infusion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate meal
Description: Carbohydrate meal intervention is characterized by the consumption of a carbohydrate-based meal right before the exercise protocol test, without consumption yerba mate infusion.
Study: NCT03369847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide, beclomethasone
Description: The inhaled corticosteroids we are using for this study are budesonide nebulized solution and beclomethasone metered-dose inhaler. Low-doses for these medications are 0.5mg/day for budesonide and 160 mcg/day for beclomethasone. Patients under 5 years of age will receive low dose budesonide solution 0.25mg/respule to be given twice a day via nebulizer. Budesonide is FDA approved for children under 5 years of age. Patients 5 years and older will receive one beclomethasone metered-dose inhaler (MDI) 40mcg/puff two puffs twice a day via spacer. Beclomethasone is FDA approved for children 5 years and older.
Study: NCT02591992

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac CT as the first diagnostic modality in suspected CAD
Description: Performation of non-invasive cardiac CT angiogram

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Invasive coronary angiography as indicated by the guidelines
Description: Patient undergoes invasive coronary angiography
Study: NCT02688569

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Chronic Widespread Pain
Description: CBT-CWP in this study involves 4 sessions of one-hour non-drug behavioral intervention. Session 1 involves education about pain and insomnia and the relationship between the two. Participants will also learn sleep hygiene and stimulus control skills. Session 3 involves teaching participants skills to limit non-sleep time in bed and thus increase sleep efficiency. Participants will also learn the relationship between pain and activity. Session 4 involves teaching participants cognitive restructuring and mindfulness skills to manage maladaptive thoughts related to pain and insomnia. Participants will also review the skills they learned and discuss the maintenance of treatment gains.
Study: NCT01106261

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metastasectomy
Description: Pulmonary Metastasectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active monitoring
Description: Active monitoring
Study: NCT01023529

Intervention type: RADIATION
Intervention: Palliative pelvic soft-tissue radiation (external beam)
Description: 3 Gy x 10-13 (range 30 - 39 Gy total)

Intervention type: RADIATION
Intervention: Palliative pelvic soft-tissue radiation (external beam)
Description: 3 Gy x 10-13 (range 30 - 39 Gy total)
Study: NCT04527757

Intervention type: PROCEDURE
Intervention: Inhalation induction
Description: For the inhalation induction sevoflurane will be used (in the mixture with O2 + air, or O2 + N2O).

Intervention type: PROCEDURE
Intervention: Intravenous induction
Description: For the intravenous induction, commonly used induction anaesthetics will be used (propofol, etomidate, ketamine, midazolam).
Study: NCT03941548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543
Description: Administered as 12 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543
Description: Administered as 12 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543 Matching Placebo
Description: Administered as tablets to aid treatment masking.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543 Matching Placebo
Description: Administered as tablets to aid treatment masking.
Study: NCT00658229

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength training group
Description: After 5-10 months on androgen deprivation therapy the patients in the intervention group go through a four months strength training intervention. The patients will perform three strength-training sessions per week, two under supervision of a sport instructor. Each session will consists of one-three sets of nine strength-training exercises, performed at an intensity of 6 or 10 repetitions of maximum (6-10 RM).
Study: NCT03663244

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR
Description: Standardised stress reduction programme with established efficacy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LSR
Description: Existing stress reduction programme in a Danish municipality
Study: NCT01389128

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-pharmacological resources
Description: A sequence of non-pharmacological resources were applied to the patient by the researcher according to uterine cervical dilation, as follows:~* Pelvic mobility on the exercise ball oriented and accompanied by the researcher for 40 minutes;~* Lumbosacral massage for a period of 40 minutes, when dilation was between 5 and 6 cm. During the procedure, the woman in labor was allowed to freely choose the most comfortable position; and,~* Warm shower with the water flow directed to the lower-back of the woman in labor, for 40 minutes, when uterine cervical dilation was equal to or higher than 7cm.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: Routine care of the institution performed by the staff, without the presence of the researcher that included offering a balanced meal, continuous support with the presence of a partner or family throughout labor, use of oxytocin when prescribed by the staff, use of drug analgesia when requested by the patient.
Study: NCT03795350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclometasone dipropionate Formoterol Fumarate Glycopyrronium Bromide
Description: single inhalation of 99mTc radiolabelled TRIMBOW pMDI (4 puffs for a total dose of 400mcg BDP, 24mcg FF, 50 mcg GB)
Study: NCT01655511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis
Description: 240 mg, solution, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis
Description: 480 mg, solution, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis
Description: TBD dose will be a single dose if \< 720 mg or a loading dose followed by additional dose if \> 720 mg.
Study: NCT02305433

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based physiotherapy (physical exercise)
Description: Each physiotherapy (physical exercise) session includes muscle strength and endurance training (especially for lower limbs), balance and coordination training and functional training. Functional training includes walking exercises and ADL (activities of daily living) exercises. In addition the physiotherapist gives counseling on nutrition.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based physiotherapy (physical exercise)
Description: Each physiotherapy (physical exercise) session includes muscle strength and endurance training (especially for lower limbs), balance and coordination training and functional training. Functional training includes walking exercises and ADL (activities of daily living) exercises. In addition the physiotherapist gives counseling on nutrition.
Study: NCT01521845

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omega 3
Description: 3 gram omega 3 (400mg EPA and 200mg DHA) 12hours before PCI
Study: NCT00777972

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets
Study: NCT03679598

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alvelestat (MPH966)
Description: Alvelestat was developed as treatment for lung diseases like Chronic Obstructive Pulmonary Disease. Alevelestat works by blocking certain proteins in the body that are responsible for inflammation and damage to the lungs that can lead to COPD symptoms.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a pill or tablet that does not contain any study drug.
Study: NCT01015703

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CoVaccine HT
Description: intramuscular injection, dose escalation
Study: NCT03990662

Intervention type: OTHER
Intervention: Physiotherapy - Manual Therapy
Description: Participants will receive four sessions of manual therapy applied to craniomandibular structures over four weeks. The application of manual therapy aims to decrease pain by treating masticatory muscle trigger points, muscle tightness, and restricted temporomandibular joint movements. Several techniques will be considered, including ventral and caudal anterior glide temporomandibular joint mobilisation, soft tissue interventions for the management of trigger points in masticatory muscles and myofascial induction therapy applied to craniomandibular structures. The structures targeted in the treatment sessions will be the temporomandibular joint, temporal muscles, masseter muscles, medial and lateral pterygoid muscles and suprahyoid muscles.
Study: NCT04550702

Intervention type: DRUG
Intervention: Mirabegron 25mg
Description: Mirabegron 25 mg per day
Study: NCT01639911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib at the assigned dose by mouth (PO) twice a day for 7 days beginning on day 1 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib at the assigned dose once a day continuously for the duration of treatment.
Study: NCT03182075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Training
Description: OCD and hoarding disorder participants will receive 14 sessions of training via computer within 3 weeks.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Computerized Training
Description: OCD and hoarding disorder participants will receive 14 sessions of training via computer within 3 weeks.
Study: NCT01711632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Patients will receive vemurafenib at a dose of 960mg orally b.i.d. continuously in cycles of 4 weeks (28 days) as outpatient. A bone marrow aspirate and/or biopsy will be performed after the first cycle for research purposes only. After the completion of the third cycle, a repeat bone marrow aspirate and/or biopsy will be performed for assessment of response and evaluation of MRD. Following the third cycle assessments, patients who achieve complete response (CR) with detectable MRD or partial response (PR) may continue with vemurafenib for up to 3 additional cycles at the treating physician's discretion (Cycles 4-6). Patients who achieve CR without MRD will be observed as part of post-treatment followup, and may be re-treated with vemurafenib after relapse (as per below). Patients who achieve no response (NR) after the initial 3 cycles of vemurafenib will be removed from the study. They will be followed every 3 months as part of posttreatment followup for a total of 12 months.
Study: NCT04267614

Intervention type: DRUG
Intervention: Etanercept
Description: Patients who received etanercept for RA
Study: NCT04632238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metrics-driven quality improvement (MDQI)
Description: The intervention broadly consists of training and coaching to clinic staff and leadership on 1) clinical quality measure monitoring; 2) clinical practice process change management; and 3) use of tools for shared decision making and patient treatment progress monitoring.
Study: NCT01763957

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Floor Muscle Training (PFMT)
Description: All subjects allocated to this group will receive one group lesson, 45 minute sessions once a week for twelve weeks. All will be encouraged to practice daily for 15-45 minutes at home. The teachers will be followed a set exercise list .
Study: NCT03024164

Intervention type: OTHER
Intervention: Treatment following current guidelines
Description: Treatment following current guidelines
Study: NCT02465060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taselisib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulixertinib
Description: Give PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Given PO
Study: NCT01654822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical application cervical spray
Description: one time (2 puffs) topical application of 100µl AV2-DM antiviral spray( containing 50% AV2-DM and 50% olive oil)on the cervix

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: topical spray on the cervix
Description: one time (2 puffs) topical spray of 100 µl (90% olive oil and 10% d-limonene) on the cervix
Study: NCT04074759

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FPT155
Description: A soluble CD80 fusion protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FPT155
Description: A soluble CD80 fusion protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: An anti-PD1 antibody
Study: NCT05995821

Intervention type: OTHER
Intervention: Collection of biological specimens
Description: Collection of tumor, blood, lymph nodes, white blood cells, mouth cells (buccal smears) scraped from the inside of your cheek, urine, saliva, or other tissue samples.
Study: NCT03412396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Undergo radical prostatectomy
Study: NCT02578368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 2600 mg/m², d1 i.v., every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: 2600 mg/m², d1 i.v., every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 200 mg/m², d1, i.v., every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: 200 mg/m², d1, i.v., every 2 weeks
Study: NCT03465956

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic Sleeve Gastrectomy
Description: Laparoscopic Sleeve Gastrectomy using the gastro-intestinal anastomosis stapler.
Study: NCT05164328

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT02454114

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HOMEFIRST
Description: HOMEFIRST patients receive monitoring and review of; vital signs, symptoms, mental state, nutrition and hydration, urine output, skin turgor and integrity, mobility, coping ability, medication concordance, smoking and nutrition and hydration. Individualised verbal and written self-management plans, a list of symptoms (including red flag symptoms) to prompt contact with the study team and a 24hr emergency contact number are provided. Clinical bloods and other investigations will be taken/requested as necessary. Questionnaires will be completed as follows; SF-12 - at recruitment and 6 weeks, CAP-SYM - at recruitment and 6 weeks. Satisfaction questionnaires are conducted over the telephone at 2 wks by an independent assessor. As part of usual clinical practice patients will have bloods and radiology requested as required.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Hospital Care
Description: No research investigations will occur except for questionnaires; as part of usual clinical practice patients will have bloods and radiology requested as desired by their usual clinical team.~SF-12 (physical and mental function) \[performed twice in total\] - at recruitment (day 0) and 6 weeks~CAP-SYM \[performed 3 times in total\] - at recruitment day 0 (twice including day minus 30) and 6 weeks~Patient (and carer/consultee) satisfaction - conducted over the telephone at 2 wks by an independent assessor.
Study: NCT04223089

Intervention type: DIAGNOSTIC_TEST
Intervention: Near Infrared Spectroscopy
Description: The Kent Camera is intended for use by healthcare professionals as a non-invasive tissue oxygenation measurement system that reports an approximate value of the following in superficial tissue:~* oxygen saturation (StO2),~* relative oxyhemoglobin level (HbO2), and~* relative deoxyhemoglobin (Hb) level~The Kent Camera displays two-dimensional color-coded images of tissue oxygenation of the scanned surface and reports multispectral tissue oxygenation measurements for selected tissue regions. The Kent Camera is indicated for use to determine oxygenation levels in superficial tissues.

Intervention type: DIAGNOSTIC_TEST
Intervention: Near Infrared Spectroscopy
Description: The Kent Camera is intended for use by healthcare professionals as a non-invasive tissue oxygenation measurement system that reports an approximate value of the following in superficial tissue:~* oxygen saturation (StO2),~* relative oxyhemoglobin level (HbO2), and~* relative deoxyhemoglobin (Hb) level~The Kent Camera displays two-dimensional color-coded images of tissue oxygenation of the scanned surface and reports multispectral tissue oxygenation measurements for selected tissue regions. The Kent Camera is indicated for use to determine oxygenation levels in superficial tissues.
Study: NCT04627545

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2h exposure to sperm for IVF
Description: Oocytes will only be briefly (2h) exposed to progressive motile sperm for insemination

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: overnight exposure to sperm for IVF
Description: Oocytes will be exposed for a longer duration (overnight, 16-20h) to progressive motile sperm for insemination
Study: NCT04021472

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text message
Description: Two months of daily text messages to support meeting a health goal
Study: NCT01654822

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cervical swab with Cervex-Brush-Combi at T0

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cervical swab with Cervex-Brush-Combi at T1

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: cervical swab with Cervex-Brush-Combi at T0
Study: NCT02621385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tradipitant
Description: test agent